Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan Dual Therapy vs Bismuth Quadruple Therapy for H. Pylori Eradication
NCT06412588Completed
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Nanjing First Hospital. Primary endpoint: Helicobacter Pylori eradication rate. Started Jun 2024; status: completed.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06412588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412588.